Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Jefferam1on Aug 01, 2018 9:13am
171 Views
Post# 28396676

RE:RE:Delay

RE:RE:DelayThe only reason they would RS is to get on NASDAQ which requires a share price of 4.00 USD

If they did their max 10:1 RS, they would need a sustainable share price of 0.40 USD to be able to list and do the RS. 

That means they probably have to be closer to 0.50 USD which is approx 0.65 CDN.

This is all good news, the earliest they do an RS is once share price climbs to 0.65 and it would be in anticipation to get listed on NASDAQ. The reason matters and I believe it would well accepted by the majority of investors. 

Now if they stay below 0.65 till trial results and then say they spike to 1.00 +, by then they may already have partnership or bought  deals sorted out that they wouldn't bother doing a RS. Or perhaps during discussions they do an RS and list on NASDAQ, which gives us more US exposure and ultimately increases SP while negotiating and we end up with an even better deal.

That's my hope.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities